Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans

There are few treatments that slow neurodegeneration in Alzheimer’s disease (AD), and while therapeutic antibodies are being investigated in clinical trials for AD treatment, their access to the central nervous system is restricted by the blood–brain barrier. This study investigates a bispecific mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Grimm, Hans Peter, Schumacher, Vanessa, Schäfer, Martin, Imhof-Jung, Sabine, Freskgård, Per-Ola, Brady, Kevin, Hofmann, Carsten, Rüger, Petra, Schlothauer, Tilman, Göpfert, Ulrich, Hartl, Maximilian, Rottach, Sylvia, Zwick, Adrian, Seger, Shanon, Neff, Rachel, Niewoehner, Jens, Janssen, Niels
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572082/
https://www.ncbi.nlm.nih.gov/pubmed/37823690
http://dx.doi.org/10.1080/19420862.2023.2261509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572082/
https://www.ncbi.nlm.nih.gov/pubmed/37823690
http://dx.doi.org/10.1080/19420862.2023.2261509

Ejemplares similares